JP2017518275A5 - - Google Patents

Download PDF

Info

Publication number
JP2017518275A5
JP2017518275A5 JP2016565267A JP2016565267A JP2017518275A5 JP 2017518275 A5 JP2017518275 A5 JP 2017518275A5 JP 2016565267 A JP2016565267 A JP 2016565267A JP 2016565267 A JP2016565267 A JP 2016565267A JP 2017518275 A5 JP2017518275 A5 JP 2017518275A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
aluminum
oxyhydroxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016565267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518275A (ja
JP6692755B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059339 external-priority patent/WO2015165966A1/en
Publication of JP2017518275A publication Critical patent/JP2017518275A/ja
Publication of JP2017518275A5 publication Critical patent/JP2017518275A5/ja
Application granted granted Critical
Publication of JP6692755B2 publication Critical patent/JP6692755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016565267A 2014-04-29 2015-04-29 アルツハイマー病(ad)の処置および予防 Active JP6692755B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14166354 2014-04-29
EP14166355.9 2014-04-29
EP14166354.2 2014-04-29
EP14166355 2014-04-29
PCT/EP2015/059339 WO2015165966A1 (en) 2014-04-29 2015-04-29 Treatment and prevention of alzheimer's disease (ad)

Publications (3)

Publication Number Publication Date
JP2017518275A JP2017518275A (ja) 2017-07-06
JP2017518275A5 true JP2017518275A5 (https=) 2018-05-31
JP6692755B2 JP6692755B2 (ja) 2020-05-13

Family

ID=53039896

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016565267A Active JP6692755B2 (ja) 2014-04-29 2015-04-29 アルツハイマー病(ad)の処置および予防

Country Status (18)

Country Link
US (1) US10478454B2 (https=)
EP (2) EP3269376B1 (https=)
JP (1) JP6692755B2 (https=)
KR (1) KR102388363B1 (https=)
CN (1) CN106659738B (https=)
AU (1) AU2015254663B2 (https=)
CA (1) CA2946928C (https=)
CY (1) CY1119674T1 (https=)
DK (1) DK3137093T3 (https=)
ES (2) ES2824763T3 (https=)
HR (1) HRP20171896T1 (https=)
HU (1) HUE037501T2 (https=)
LT (1) LT3137093T (https=)
NO (1) NO3137093T3 (https=)
PL (1) PL3137093T3 (https=)
PT (1) PT3137093T (https=)
SI (1) SI3137093T1 (https=)
WO (1) WO2015165966A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102460465B1 (ko) 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병(ad)의 치료 및 예방
FI3137094T3 (fi) 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3440593A (en) * 1993-01-14 1994-08-15 Nelson Arispe Methods and compositions for blocking amyloid protein ion channels
WO1999009981A1 (en) * 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CA2793580A1 (en) * 2010-03-29 2011-10-06 Novartis Ag Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
KR102460465B1 (ko) * 2014-04-29 2022-10-27 어드밴티지 테라퓨틱스, 인코포레이티드 알츠하이머병(ad)의 치료 및 예방
FI3137094T3 (fi) * 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen

Similar Documents

Publication Publication Date Title
RU2495662C2 (ru) Антимикробные композиции с контролируемым высвобождением для лечения ушных заболеваний
JP2015526467A5 (https=)
JP2018138578A5 (https=)
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
JP2011518119A5 (https=)
JP2012051891A5 (https=)
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
RU2016119746A (ru) Стабильный состав инсулина глулизин
JP2013513612A5 (https=)
JP2017533972A5 (https=)
JP2016503058A5 (https=)
EP4700016A3 (en) Pharmaceutical agent for treating amyotrophic lateral sclerosis or suppressing disease progress thereof
EA201300314A1 (ru) Композиции и лекарственное средство для лечения глазных болезней, устройство, содержащее композиции и лекарственное средство
JP2017518275A5 (https=)
KR20180115295A (ko) 폴리쿼터늄을 함유하는 항미생물 조성물
JP2020536098A5 (https=)
JP2019532095A5 (https=)
JP2017514831A5 (https=)
CA2688047A1 (en) Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration
JP2017515812A5 (https=)
JP2019507174A5 (https=)
KR20170124322A (ko) 알러지 질환 치료제 전달을 위한 용해성 미세바늘 패치
WO2007092452A2 (en) Formulation and method of use for animal ear treatment and homeopathic animal ear treatment
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
SI3137093T1 (en) Treatment and prevention of Alzheimer's disease